Provided by Tiger Trade Technology Pte. Ltd.

Anixa Biosciences

2.69
-0.1100-3.93%
Post-market: 2.690.00000.00%19:45 EDT
Volume:353.74K
Turnover:954.48K
Market Cap:93.51M
PE:-8.68
High:2.80
Open:2.80
Low:2.66
Close:2.80
52wk High:5.46
52wk Low:2.32
Shares:34.76M
Float Shares:32.61M
Volume Ratio:0.85
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3100
EPS(LYR):-0.3367
ROE:-73.17%
ROA:-41.93%
PB:6.46
PE(LYR):-7.99

Loading ...

Anixa Biosciences CEO Amit Kumar Buys $15,200 Common Shares

Reuters
·
Jul 13

Anixa Advances Ovarian Cancer CAR-T Trial to Highest Dose Cohort in Phase 1 Study

Reuters
·
Jul 06

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

THOMSON REUTERS
·
Jul 06

Anixa Biosciences - Five Patients Surpass One Year Survival with Durations up to 28 Months

THOMSON REUTERS
·
Jul 06

Anixa Biosciences - no Dose-limiting Toxicities Observed up to Prior Dose Level of 3x10⁶/kg CAR-T Cells

THOMSON REUTERS
·
Jul 06

Anixa Biosciences Coverage Assumed by D. Boral Capital at Buy

Dow Jones
·
Jul 01

Anixa Biosciences assumed with a Buy at D. Boral Capital

TIPRANKS
·
Jun 30

Anixa Biosciences granted first Korean patent for breast cancer vaccine

TIPRANKS
·
Jun 29

Anixa Biosciences - Granted First Korean Patent for Breast Cancer Vaccine Through 2040

THOMSON REUTERS
·
Jun 29

Anixa Biosciences reports results from two clinical-stage immunotherapy programs

TIPRANKS
·
Jun 26

Anixa Reports Phase 1 Breast Cancer Vaccine Data Showing Immune Responses in 74% of Participants

Reuters
·
Jun 26

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

THOMSON REUTERS
·
Jun 26

Penny Stocks To Watch For Growth In June 2026

Simply Wall St.
·
Jun 19

Anixa Biosciences director Lewis H. Titterton Jr buys $7,487 of common shares

Reuters
·
Jun 17

Anixa Biosciences CEO Makes Bold Insider Move That Could Turn Heads

TIPRANKS
·
Jun 17

Anixa Biosciences CEO Amit Kumar acquires 21,000 common shares for $52,500

Reuters
·
Jun 16

Analysts’ Top Healthcare Picks: Alto Neuroscience, Inc. (ANRO), Anixa Biosciences (ANIX)

TIPRANKS
·
Jun 11

Anixa Biosciences to present ovarian cancer CAR-T data at New York Academy of Sciences cancer immunotherapy symposium

Reuters
·
Jun 11

Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

THOMSON REUTERS
·
Jun 11

Anixa Biosciences Q2 EPS $(0.07) Beats $(0.09) Estimate

Benzinga Earnings
·
Jun 11